Alzheimer’s Disease: Erythrocyte 2,3-diphosphoglycerate Content and Circulating Erythropoietin

Author(s): Petter Järemo*, Alenka Jejcic, Vesna Jelic, Tasmin Shahnaz, Homira Behbahani, Magnus Oweling, Bengt Winblad.

Journal Name: Current Alzheimer Research

Volume 16 , Issue 9 , 2019

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Background: Alzheimer’s Disease (AD) features the accumulation of β-amyloid in erythrocytes. The subsequent red cell damage may well affect their oxygen-carrying capabilities. 2,3- diphosphoglycerate (2,3-DPG) binds to the hemoglobin thereby promoting oxygen release. It is theorized that 2,3-DPG is reduced in AD and that the resulting hypoxia triggers erythropoietin (EPO) release.

Methods & Objective: To explore this theory, we analyzed red cell 2,3-DPG content and EPO in AD, mild cognitive impairment, and the control group, subjective cognitive impairment.

Results: We studied (i) 2,3-DPG in red cells, and (ii) circulating EPO in AD, and both markers were unaffected by dementia. Disturbances of these oxygen-regulatory pathways do not appear to participate in brain hypoxia in AD.

Keywords: Alzheimer, 2, 3-diphosphoglycerate, erythrocytes, erythropoietin, β-amyloid, cognitive impairment.

[1]
Järemo P, Milovanovic M, Nilsson S, Buller C, Post C, Winblad B. Alzheimer’s disease is characterized by more low-density erythrocytes with increased volume and enhanced beta-amyloid x-40 content. J Intern Med 270(5): 489-92. (2011).
[2]
Järemo P, Jejcic A, Jelic V, Shahnaz T, Oweling M, Winblad B, et al. Alzheimer’s disease: Amyloid beta peptide isoform distributions in erythrocytes and in the cerebrospinal fluid show substantial similarities. Submitted (2019).
[3]
Kiko T, Nakagawa K, Satoh A, Tsuduki T, Furukawa K, Arai H, et al. Amyloid beta levels in human red blood cells. PLoS One 7(11)e49620 (2012).
[4]
Chang CY, Liang HJ, Chow SY, Chen SM, Liu DZ. Hemorheological mechanisms in Alzheimer′s disease. Microcirculation 14(6): 627-34. (2007).
[5]
Thomas HM, Lefrak SS, Irwin RS, Fritts RS, Caldwell PR. The oxyhemoglobin dissociation curve in health and disease. Role of 2,3-diphosphoglycerate. Am J Med 57(3): 331-48. (1974).
[6]
Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256(3): 240-6. (2004).
[7]
Sharma S, Brugnara C, Betensky RA, Waikar SS. Reductions in red blood cell 2,3-diphosphoglycerate concentration during continuous renal replacement therapy. Clin J Am Soc Nephrol 10(1): 74-9. (2015).
[8]
Kosenko EA, Aliev G, Kaminsky YG. Relationship between chronic disturbance of 2,3-diphosphoglycerate metabolism in erythrocytes and Alzheimer disease. CNS Neurol Disord Drug Targets 15(1): 113-23. (2016).


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 16
ISSUE: 9
Year: 2019
Page: [834 - 835]
Pages: 2
DOI: 10.2174/1567205016666190827120108
Price: $65

Article Metrics

PDF: 25
HTML: 3